Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells

Hui Wen Chiu, Yin Chiu Tseng, Yung Ho Hsu, Yuh Feng Lin, Ning Ping Foo, How Ran Guo, Ying Jan Wang

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Sarcoma is a rare form of cancer that differs from the much more common carcinomas because it occurs in a distinct type of tissue. Many patients of sarcoma have poor response to chemotherapy and an increased risk for local recurrence. Arsenic trioxide (ATO) is used to treat certain types of leukemia. Recently, data have revealed that ATO induces sarcoma cell death in several types of solid tumor cell lines. In the present study, we investigated whether ATO induces cancer cell death and elucidated the underlying anti-cancer mechanisms. Our results showed that ATO caused concentration- and time-dependent cell death in human osteosarcoma and fibrosarcoma cells. The types of cell death that were induced by ATO were primarily autophagy and apoptosis. Furthermore, ATO activated p38, JNK and AMPK and inhibited the Akt/mTOR signaling pathways. Specifically, we found that ATO induced endoplasmic reticulum (ER) stress and suppressed proteasome activation in two types of sarcoma cell lines. However, the level of proteasome inhibition in osteosarcoma cells was lower than in fibrosarcoma cells. Thus, we used combined treatment with ATO and a proteasome inhibitor to examine the antitumor activity in fibrosarcoma cells. The data indicated showed that the combination treatment of ATO and MG132 (a proteasome inhibitor) resulted in synergistic cytotoxicity. In a fibrosarcoma xenograft mouse model, the combined treatment significantly reduced tumor progression. Immunohistochemical studies revealed that combined treatment induced autophagy and apoptosis. In summary, our results suggest a potential clinical application of ATO in sarcoma therapy and that combined treatment with a proteasome inhibitor can increase the therapeutic efficacy.

Original languageEnglish
Pages (from-to)762-772
Number of pages11
JournalCancer Letters
Volume356
Issue number2
DOIs
Publication statusPublished - Jan 28 2015

Fingerprint

Endoplasmic Reticulum Stress
Proteasome Endopeptidase Complex
Ubiquitin
Sarcoma
Cell Death
Fibrosarcoma
Proteasome Inhibitors
Autophagy
Osteosarcoma
Therapeutics
Neoplasms
arsenic trioxide
Apoptosis
AMP-Activated Protein Kinases
Tumor Cell Line
Heterografts
Leukemia
Carcinoma
Recurrence
Drug Therapy

Keywords

  • Apoptosis
  • Arsenic trioxide
  • Autophagy
  • Endoplasmic reticulum stress
  • Sarcoma
  • Ubiquitin-proteasome system

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells. / Chiu, Hui Wen; Tseng, Yin Chiu; Hsu, Yung Ho; Lin, Yuh Feng; Foo, Ning Ping; Guo, How Ran; Wang, Ying Jan.

In: Cancer Letters, Vol. 356, No. 2, 28.01.2015, p. 762-772.

Research output: Contribution to journalArticle

@article{5ee1c00a207a4436b070e407e696b3ce,
title = "Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells",
abstract = "Sarcoma is a rare form of cancer that differs from the much more common carcinomas because it occurs in a distinct type of tissue. Many patients of sarcoma have poor response to chemotherapy and an increased risk for local recurrence. Arsenic trioxide (ATO) is used to treat certain types of leukemia. Recently, data have revealed that ATO induces sarcoma cell death in several types of solid tumor cell lines. In the present study, we investigated whether ATO induces cancer cell death and elucidated the underlying anti-cancer mechanisms. Our results showed that ATO caused concentration- and time-dependent cell death in human osteosarcoma and fibrosarcoma cells. The types of cell death that were induced by ATO were primarily autophagy and apoptosis. Furthermore, ATO activated p38, JNK and AMPK and inhibited the Akt/mTOR signaling pathways. Specifically, we found that ATO induced endoplasmic reticulum (ER) stress and suppressed proteasome activation in two types of sarcoma cell lines. However, the level of proteasome inhibition in osteosarcoma cells was lower than in fibrosarcoma cells. Thus, we used combined treatment with ATO and a proteasome inhibitor to examine the antitumor activity in fibrosarcoma cells. The data indicated showed that the combination treatment of ATO and MG132 (a proteasome inhibitor) resulted in synergistic cytotoxicity. In a fibrosarcoma xenograft mouse model, the combined treatment significantly reduced tumor progression. Immunohistochemical studies revealed that combined treatment induced autophagy and apoptosis. In summary, our results suggest a potential clinical application of ATO in sarcoma therapy and that combined treatment with a proteasome inhibitor can increase the therapeutic efficacy.",
keywords = "Apoptosis, Arsenic trioxide, Autophagy, Endoplasmic reticulum stress, Sarcoma, Ubiquitin-proteasome system",
author = "Chiu, {Hui Wen} and Tseng, {Yin Chiu} and Hsu, {Yung Ho} and Lin, {Yuh Feng} and Foo, {Ning Ping} and Guo, {How Ran} and Wang, {Ying Jan}",
year = "2015",
month = "1",
day = "28",
doi = "10.1016/j.canlet.2014.10.025",
language = "English",
volume = "356",
pages = "762--772",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells

AU - Chiu, Hui Wen

AU - Tseng, Yin Chiu

AU - Hsu, Yung Ho

AU - Lin, Yuh Feng

AU - Foo, Ning Ping

AU - Guo, How Ran

AU - Wang, Ying Jan

PY - 2015/1/28

Y1 - 2015/1/28

N2 - Sarcoma is a rare form of cancer that differs from the much more common carcinomas because it occurs in a distinct type of tissue. Many patients of sarcoma have poor response to chemotherapy and an increased risk for local recurrence. Arsenic trioxide (ATO) is used to treat certain types of leukemia. Recently, data have revealed that ATO induces sarcoma cell death in several types of solid tumor cell lines. In the present study, we investigated whether ATO induces cancer cell death and elucidated the underlying anti-cancer mechanisms. Our results showed that ATO caused concentration- and time-dependent cell death in human osteosarcoma and fibrosarcoma cells. The types of cell death that were induced by ATO were primarily autophagy and apoptosis. Furthermore, ATO activated p38, JNK and AMPK and inhibited the Akt/mTOR signaling pathways. Specifically, we found that ATO induced endoplasmic reticulum (ER) stress and suppressed proteasome activation in two types of sarcoma cell lines. However, the level of proteasome inhibition in osteosarcoma cells was lower than in fibrosarcoma cells. Thus, we used combined treatment with ATO and a proteasome inhibitor to examine the antitumor activity in fibrosarcoma cells. The data indicated showed that the combination treatment of ATO and MG132 (a proteasome inhibitor) resulted in synergistic cytotoxicity. In a fibrosarcoma xenograft mouse model, the combined treatment significantly reduced tumor progression. Immunohistochemical studies revealed that combined treatment induced autophagy and apoptosis. In summary, our results suggest a potential clinical application of ATO in sarcoma therapy and that combined treatment with a proteasome inhibitor can increase the therapeutic efficacy.

AB - Sarcoma is a rare form of cancer that differs from the much more common carcinomas because it occurs in a distinct type of tissue. Many patients of sarcoma have poor response to chemotherapy and an increased risk for local recurrence. Arsenic trioxide (ATO) is used to treat certain types of leukemia. Recently, data have revealed that ATO induces sarcoma cell death in several types of solid tumor cell lines. In the present study, we investigated whether ATO induces cancer cell death and elucidated the underlying anti-cancer mechanisms. Our results showed that ATO caused concentration- and time-dependent cell death in human osteosarcoma and fibrosarcoma cells. The types of cell death that were induced by ATO were primarily autophagy and apoptosis. Furthermore, ATO activated p38, JNK and AMPK and inhibited the Akt/mTOR signaling pathways. Specifically, we found that ATO induced endoplasmic reticulum (ER) stress and suppressed proteasome activation in two types of sarcoma cell lines. However, the level of proteasome inhibition in osteosarcoma cells was lower than in fibrosarcoma cells. Thus, we used combined treatment with ATO and a proteasome inhibitor to examine the antitumor activity in fibrosarcoma cells. The data indicated showed that the combination treatment of ATO and MG132 (a proteasome inhibitor) resulted in synergistic cytotoxicity. In a fibrosarcoma xenograft mouse model, the combined treatment significantly reduced tumor progression. Immunohistochemical studies revealed that combined treatment induced autophagy and apoptosis. In summary, our results suggest a potential clinical application of ATO in sarcoma therapy and that combined treatment with a proteasome inhibitor can increase the therapeutic efficacy.

KW - Apoptosis

KW - Arsenic trioxide

KW - Autophagy

KW - Endoplasmic reticulum stress

KW - Sarcoma

KW - Ubiquitin-proteasome system

UR - http://www.scopus.com/inward/record.url?scp=84919483390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919483390&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2014.10.025

DO - 10.1016/j.canlet.2014.10.025

M3 - Article

C2 - 25449439

AN - SCOPUS:84919483390

VL - 356

SP - 762

EP - 772

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -